Browsing by Author Lebbe, Celeste

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Davies, Michael; Del Vecchio, M; Flaherty, Keith; Grob, Jean-Jacques; Hogg, David; Huang, Yingjie; Lebbe, Celeste; Lesimple, Thierry; Márquez-Rodas, Ivan; Meyer, Nicolas; Mookerjee, Bijoyesh P; Mortier, Laurent; Moschos, S; Robert, Caroline; Saiag, Philippe; Thomas, Luc; Zhang, Ying; Northern Clinical School: MedicineDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, The Lancet Oncology, vol.18, 7, 2017,pp 863-873
2015Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaLong, Georgina; Amonkar, Mayur M; Bondarenko, Igor; de Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Lebbe, Celeste; Levchenko, Evgeny; Schadendorf, Dirk; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreHealth-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma, European Journal of Cancer, vol.51, 7, 2015,pp 833-840
2017Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialMcNeil, Catriona; Arance, A; Ascierto, Paolo A; Bastholt, Lars; Chiarion-Sileni, Vanna; Del Vecchio, Michele; et al, Various; Hamid, Omid; Lebbe, Celeste; Mackiewicz, Andrzej; Robert, Caroline; Rutkowski, Piotr; Central Clinical School: MedicineIpilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial, The Lancet Oncology, vol.18, 5, 2017,pp 611-622
2013Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaKefford, Richard (Rick); Long, Georgina; Amaravadi, Ravi; Arya, Niki; Ascierto, Paolo; et al, Various; Grob, Jean-Jacques; Guckert, Mary; Hamid, Omid; Kim, Kevin; Lebbe, Celeste; Minor, David; O'Hagan, Anne; Ribas, Antoni; Schadendorf, D; Simeone, Ester; Wilhelm, Tabea; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 26, 2013,pp 3205-3211